Plasmagen Biosciences taps into the niche Indian Biopharmaceutical market with the launch of CSL’s Haemocomplettan® P.
Haemocomplettan® P will cater to the 1,50,000 cardiac surgeries and over 1,800 liver transplant patients who are at risk of massive bleeding due to acquired hypofibrinogenemia. MUMBAI, 20th JUNE, 2024 (GPN): Plasmagen Biosciences Private Limited…